For investee companiesPortfolio Companies
Capital connected to execution.
Faster path to profitabilityTarget · Illustrative
00Abu Dhabi · Healthcare Investment & Operating Platform
MedTech ownership, manufactured and commercialized from the GCC.
Merova Healthcare Holding combines strategic investment, Abu Dhabi manufacturing, and regional commercialization to accelerate proven healthcare products across MENA, India, and global markets.
Platform · Q2 2026
- GCC Healthcare Market$0B+
- GCC Medical Imports0%+
- Target Raise$0M
- First Close Target$0M
- Term Sheet Signed$0M
- Minimum Investment$0M
Targets and projections. Projected, actual results may vary.
Healthcare products rarely scale through capital alone. They scale when ownership, manufacturing, market access, and execution move as one system.
03The Operating Model
One platform. Three operating engines. One value creation model.
04Value Creation
Value is created when capital is connected to execution.
For qualified institutional investorsInvestors
Dual-track returns.
Dual-track investor returnsTarget · Illustrative
Illustrative model. Targets and projections only. Projected, actual results may vary.
The Opportunity
05The Market Gap
A fragmented healthcare market creates an operating opportunity.
01
No local innovation infrastructure
02
85%+ of GCC medical products are imported
03
Investors seek cash flow and venture upside
04
Fragmented investment & commercialization ecosystem
Capital, manufacturing, regulatory access and commercialization currently operate as separate silos across the region. Merova connects them under one integrated platform — designed to compress timelines, reduce friction, and capture in-country value.
Integrated → Merova
06Merova Ventures
Strategic ownership in emerging-growth MedTech.
IP-backed companies with approvals in the USA and Europe, screened for GCC manufacturing fit and regional commercialization upside.
Stage Allocation · Target
- Emerging Growth0%
- Follow-on0%
- Late Stage0%
Target Return Profile
- Ventures Multiple0–5x
- Ventures IRR0–40%
- Cumulative Platform> 0%
Investment Screening
- Proprietary MedTech with patent protection
- CE Marked and/or USA FDA approved
- UAE manufacturing & marketing opportunities
- Large addressable markets
- Validated demand with adequate pricing
- Emerging growth phase with attractive valuations
07Merova CMO
Manufacturing selected healthcare products in Abu Dhabi.
A cost-plus contract manufacturing model built around portfolio companies and proprietary healthcare products. Made in Emirates — in-country value creation, supply-chain resilience, and a credible middle ground between US/EU CMOs.
ProductCategoryPeak RevUnits
ReadyfusorDrug-device combo · acute pain$3M1M / yr
ZingoDrug-device combo · needle-stick pain$7M15M / yr
Smart Scope® CXAI cervical cancer diagnostic$5M10M / yr
Revian Hair DeviceLED hair regrowth system$15M500K / yr
Axon HeadsetVermillion Health · BCI chronic pain$15M1M / yr
All revenue figures are peak targets. Projected, actual results may vary.Explore Merova CMO
08Merova Care Solutions
Regional commercialization for differentiated healthcare products.
Featured · BlockbusterIndia + MENA
Socazolimab
Monoclonal antibody for cervical cancer treatment. Exclusive India + MENA license from BioQ and Lee's Pharm. Paired with Smart Scope® CX, Periwinkle's AI cervical cancer diagnostic device.
Projected Peak Revenue> $450M[Target]
- SocazolimabCervical cancer mAb$450M
- AxonVermillion Health · chronic pain$300M
- CapniaNeonatal jaundice diagnostic$100M
- Smart Scope® CXPeriwinkle · cervical cancer$50M
- Revian Hair DeviceLED hair regrowth$30M
All revenue figures are peak targets. Projected, actual results may vary.Explore Care Solutions
09Portfolio Pipeline
A platform built around differentiated healthcare products.
01Drug-Device Combination
BioQ Pharma
Proprietary invenious™ infusion platform. Four approved products with 44 global marketing authorizations and 50+ US patents across pain, anesthesia and oncology.
CMOCare Solutions
02AI-Enabled Diagnostics
Periwinkle Technologies
Smart Scope® CX detects cervical cancer in under five minutes, offline-capable. Pre-IPO. Pipeline includes oral and breast cancer screening.
VenturesCMOCare Solutions
03Neurotechnology
Exsurgo 2.0
Axon — a clinically validated BCI headset for chronic pain. 30-minute at-home sessions with remote monitoring. Hardware plus subscription model.
VenturesCare Solutions
04AI Cardiovascular Diagnostics
CorVista
First non-invasive point-of-care cardiovascular test. AI cloud results in ~30 minutes. No radiation, no capital equipment, per-scan billing.
VenturesCare Solutions
05Therapeutic Devices
Revian
FDA-cleared LED hair regrowth platform. 65+ patents and ~75% gross margins. Channels across physicians, affiliates and DTC.
VenturesCMOCare Solutions
06Cancer Diagnostics
Vigilant Biosciences
OraFusion — chairside oral cancer risk assessment combining saliva biomarkers, clinical factors and AI. Recurring consumables business model.
VenturesCare Solutions
07Aesthetic Laser Technology
Bellamia
Botticelli™ Athena and Primavera — multi-wavelength skin rejuvenation platforms. Five awarded patents. Razor / razor-blade revenue model.
VenturesCMO
08Neurotechnology · Devices
Vermillion Health
Non-invasive EEG-based chronic pain treatment. Hardware plus SaaS subscription, addressing a large global market without drugs.
VenturesCMOCare Solutions
09Diagnostics
Capnia
Non-invasive neonatal jaundice diagnostic device. Quick and endorsed by the APA. Large addressable market in GCC, MENA and India.
VenturesCare Solutions
Anchored in the Region
10Why Abu Dhabi · GCC
Built from Abu Dhabi for regional healthcare scale.
A strategic position at the intersection of MENA, India and global markets, with a regulatory and industrial environment built for institutional-grade healthcare investment and manufacturing.
- 01$60B+ GCC healthcare market
- 0285%+ of products currently imported
- 03Manufacturing and logistics advantage
- 04MENA + India expansion pathways
- 05In-country value creation · Made in Emirates
Schematic of regional reach. Lines indicate commercial corridors from Abu Dhabi across MENA and India.
11The ROVA Framework
Why Merova is unparalleled in the Middle East.
Regional Leadership
Pioneering GCC-based healthcare manufacturing and marketing, reducing dependence on global supply chains.
Optimised Market Access
Direct access to GCC and Indian markets enables rapid expansion and strong commercial positioning.
Value Creation Model
Combining equity growth and recurring operational income for superior risk-adjusted investor returns.
Integrated Approach
Investment, manufacturing and distribution operating as one unified platform — efficiency and control.
12Leadership
An execution team across healthcare, manufacturing, finance, and regional markets.
- Director
Manufacturing plants across the UAE in pharma and MedTech. Extensive investing experience across sectors and asset classes.
13Investor Access
A dual-track platform for healthcare value creation.
Combining venture upside from emerging-growth MedTech investments with recurring operating dividends from manufacturing and commercialization — one integrated return profile for qualified institutional investors.
All financial figures are targets, projections, or illustrative examples and are subject to material risk. Projected, actual results may vary.
Target Returns
- Cumulative IRR> 0%
- Ventures Multiple0–5x
- Ventures IRR0–40%
- Operating IRR0%
Capital Structure
- Total Target Raise$0M
- First Close Target$0M
- Term Sheet Signed$0M
- Minimum Investment$0M
- SAFE$0M · 25% disc.
Corporate StructureADGM · UAE
Merova Healthcare Holding Limited (ADGM) with wholly owned UAE mainland subsidiaries: Merova Ventures Holding, Merova CMO, and Merova Care Solutions.
14From Opportunity to Scale
Source → Manufacture → Commercialize → Distribute Returns.
01Source
Originate proprietary, IP-backed MedTech with approvals in the USA and Europe.
02Evaluate
Screen for valuation, market fit, regulatory pathway and GCC manufacturability.
03Invest
Take strategic ownership through Class A Preferred at the holding level.
04Manufacture
Move production into Abu Dhabi under a cost-plus model — Made in Emirates.
05Register
Obtain UAE MoH approval and regional regulatory licenses.
06Commercialize
Market through hospital networks across the GCC and key MENA markets.
07Scale
Sublicense and expand into MENA, India and adjacent emerging markets.
08Distribute Returns
Pay venture exits and operating dividends through the dual-track return model.
Merova is building an integrated healthcare product platform where ownership, manufacturing, and commercialization operate as one system.
16Build With Merova
Build healthcare value through an integrated operating platform.
Whether you are an investor, MedTech founder, healthcare company, manufacturer, or strategic partner, Merova is designed to connect capital, production, and market access into one platform.